Showing results (181-190 of 9,860) with videos related to
Sort By:
Pageof 986
BMC Medical Education|October 31, 2025
Large language models as educational collaborators: developing non-conventional teaching aids in pharmacology & therapeuticsKannan Sridharan, Gowri SivaramakrishnanTropical Diseases, Travel Medicine and Vaccines|October 4, 2025
Global research trends in BPaL and BPaLM regimens for drug-resistant tuberculosis: a bibliometric analysisKannan Sridharan, Gowri SivaramakrishnanBMC Medical Education|October 16, 2025
Less is more? A systematic review and network meta-analysis on MCQ option numbersKannan Sridharan, Gowri SivaramakrishnanJournal of Xenobiotics|September 22, 2025
Adverse Event Signals Associated with Beta-Lactamase Inhibitors: Disproportionality Analysis of USFDA Adverse Event Reporting SystemKannan Sridharan, Gowri SivaramakrishnanJournal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|August 15, 2021
A liquid chromatography-tandem mass spectrometry method for the analysis of primary aromatic amines in human urineSridhar Chinthakindi, Kurunthachalam KannanScientific Reports|February 13, 2025
An efficient approach on risk factor prediction related to cardiovascular disease around Kumbakonam, Tamil Nadu, India, using unsupervised machine learning techniquesK Kannan, A MenagaJournal of Clinical Lipidology|February 9, 2025
Ezetimibe-associated rhabdomyolysis: A comprehensive assessment of the USFDA adverse event reporting system using disproportionality analysis, case reviews, and meta-analysis of randomized clinical trialsKannan Sridharan, Gowri SivaramakrishnanExpert Opinion on Drug Safety|December 11, 2024
Anticoagulant-associated calciphylaxis: analysis of USFDA adverse event report system and clinical feature analysis of reported casesKannan Sridharan, Gowri SivaramakrishnanExpert Opinion on Drug Safety|August 14, 2024
A pharmacovigilance study assessing risk of angioedema with angiotensin receptor blockers using the US FDA Adverse Event Reporting SystemKannan Sridharan, Gowri SivaramakrishnanExpert Opinion on Drug Safety|July 5, 2024
Risk of limb amputation and bone fractures with sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regressionKannan Sridharan, Gowri SivaramakrishnanPageof 986